Actively Recruiting
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients: A Six-month Prospective Study
Led by Oman Ministry of Health · Updated on 2026-03-24
38
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of a six-month treatment with the selective SGLT2 inhibitor, dapagliflozin, in patients with end-stage kidney disease who are on chronic peritoneal dialysis. This study includes both diabetic and non-diabetic patients and aims to understand how dapagliflozin impacts dialysis adequacy, ultrafiltration volume, and urine output. The trial is an open-label, single-arm interventional study conducted at Nizwa Hospital. Participants will receive dapagliflozin 10 mg once daily for six months. The study will monitor clinical and laboratory parameters at the start, three months, and six months after beginning treatment. The focus is on measuring changes in ultrafiltration volume, dialysis adequacy as measured by Kt/V, and 24-hour urine volume. The study includes thirty patients undergoing peritoneal dialysis. Throughout the study, participants will have assessments at baseline, three months, and six months to evaluate blood glucose levels, ultrafiltration volume, and residual kidney function. Researchers will track laboratory and clinical data, including inflammatory markers and dialysis performance. Safety and treatment effects will be monitored, with the total participation lasting six months.
CONDITIONS
Brief Title
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 13 years or older
- Any gender
- Undergoing chronic peritoneal dialysis
- Urine output of at least 150 ml per 24 hours
You will not qualify if you...
- Age less than 13 years
- Type 1 diabetes mellitus
- Recurrent urinary tract infections or peripheral vascular disease
- Urine output less than 150 ml per 24 hours
- Recurrent hypoglycemic episodes
- Acute or chronic liver disease
- Refusal to participate in the study
- Peritoneal dialysis catheter-related peritonitis within the last 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants receive the selective SGLT2 inhibitor Dapagliflozin alongside their chronic peritoneal dialysis to examine its effects on ultrafiltration volume, renal function, and blood glucose.
Regular visits during the 6 months of treatment
Trial Site Locations
Total: 1 location
1
Jehad Badawi AL LAHAM
Nizwa, Oman
Actively Recruiting
Research Team
J
Jehad Badawi B AL LAHAM
J
Jehad Badawi B AL LAHAM
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here